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BSTRACT
 
Background
 
In late 1996, vancomycin-resistant en-
terococci were first detected in the Siouxland region
of Iowa, Nebraska, and South Dakota. A task force was
created, and in 1997 the assistance of the Centers for
Disease Control and Prevention was sought in assess-
ing the prevalence of vancomycin-resistant entero-
cocci in the region’s facilities and implementing rec-
ommendations for screening, infection control, and
education at all 32 health care facilities in the region.
 
Methods
 
The infection-control intervention was
evaluated in October 1998 and October 1999. We per-
formed point-prevalence surveys, conducted a case–
control study of gastrointestinal colonization with
vancomycin-resistant enterococci, and compared in-
fection-control practices and screening policies for
vancomycin-resistant enterococci at the acute care
and long-term care facilities in the Siouxland region.
 
Results
 
Perianal-swab samples were obtained from
1954 of 2196 eligible patients (89 percent) in 1998 and
1820 of 2049 eligible patients (89 percent) in 1999.
The overall prevalence of vancomycin-resistant entero-
cocci at 30 facilities that participated in all three years
of the study decreased from 2.2 percent in 1997 to 1.4
percent in 1998 and to 0.5 percent in 1999 (P<0.001
by chi-square test for trend). The number of facilities
that had had at least one patient with vancomycin-
resistant enterococci declined from 15 in 1997 to 10
in 1998 to 5 in 1999. At both acute care and long-term
care facilities, the risk factors for colonization with van-
comycin-resistant enterococci were prior hospitaliza-
tion and treatment with antimicrobial agents. Most
of the long-term care facilities screened for vancomy-
cin-resistant enterococci (26 of 28 in 1998 [93 per-
cent] and 23 of 25 in 1999 [92 percent]) and had in-
fection-control policies to prevent the transmission
of vancomycin-resistant enterococci (22 of 25 [88 per-
cent] in 1999). All four acute care facilities had screen-
ing and infection-control policies for vancomycin-
resistant enterococci in 1998 and 1999.
 
Conclusions
 
An active infection-control interven-
tion, which includes the obtaining of surveillance
cultures and the isolation of infected patients, can re-
duce or eliminate the transmission of vancomycin-
resistant enterococci in the health care facilities of a
region. (N Engl J Med 2001;344:1427-33.)
 
Copyright © 2001 Massachusetts Medical Society.
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URING the past decade, vancomycin-
resistant enterococci have emerged and be-
come endemic at many health care facilities
in the United States.
 
1-6
 
 A major impedi-
ment to control is the large, unrecognized population
of patients who are colonized with vancomycin-resist-
ant enterococci and who thus can serve as a reservoir
for transmission.
 
7-9
 
 Colonization with vancomycin-
resistant enterococci has been associated with pro-
gression to infection.
 
8
 
 Studies suggest that once
vancomycin-resistant enterococci are introduced in
a facility, and particularly after they have spread to
multiple patients or wards, control is very difficult.
 
6-8
 
Between December 1996 and April 1997, the num-
ber of isolates of vancomycin-resistant enterococci
increased from 0 to 63 at health care facilities in the
Siouxland region of Iowa, Nebraska, and South Da-
kota, which has a population of 135,000. A task force
was formed, and in July 1997 the Hospital Infections
Program of the Centers for Disease Control and Pre-
vention (CDC) was invited to assist in an investiga-
tion. The prevalence of vancomycin-resistant entero-
cocci at the 32 facilities (4 acute care and 28 long-term
care facilities) in the region was determined, and risk
factors for vancomycin-resistant enterococci were as-
sessed.
 
10
 
 On the basis of these findings, an intervention
program was initiated. We returned on October 5,
1998, and October 25, 1999, to determine the prev-
alence of gastrointestinal colonization with vancomy-
cin-resistant enterococci 14 and 26 months, respec-
tively, after the initial prevalence survey and to evaluate
the effect of the intervention.
 
METHODS
 
The Task Force
 
In spring 1997, a meeting with representatives of health care
facilities in the Siouxland region of Iowa, Nebraska, and South
Dakota was held to discuss the sudden increase in the number of
isolates of vancomycin-resistant enterococci at these facilities, and
a task force was formed that included public health workers and
personnel from acute care and long-term care facilities. On the
basis of the initial results,
 
10
 
 a strategy to decrease the transmission
D
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of vancomycin-resistant enterococci was developed. The guidelines
of the task force
 
11
 
 were adapted from the CDC recommendations
 
12
 
(Table 1). In April 1998, after review by the Hospital Infections
Program of the CDC and the Iowa Department of Health, the
guidelines were disseminated to all 32 health care facilities in the
Siouxland region. 
 
Study Participants
 
In collaboration with the Siouxland District Health Department,
the task force, the state health departments of the three states in-
volved, and the Indian Health Service, we invited the same 32 fa-
cilities in the region that took part in the 1997 study to participate
in the 1998 and 1999 studies.
 
10
 
 Eligible participants included all
nonpsychiatric inpatients who were 18 years of age or older. All
samples were collected by using premoistened swabs during three
successive days in both 1998 and 1999. Each patient was assigned
a number by the facility personnel and was not identified by name.
At the time of sample collection, oral consent was obtained.
 
Microbiologic Methods
 
A perianal swab, defined as a swab taken from the anal verge,
without rectal insertion, was obtained from all participants except
those with a colostomy or ileostomy stoma. Swabs from the latter
patients were obtained from the junction of the epidermal and the
mucosal surfaces. All swabs were streaked onto bile esculin azide
with agar medium containing 6 µg of vancomycin per milliliter
(Becton Dickinson, Cockeysville, Md.) and incubated at 35°C for
48 hours. Colonies with morphologic features consistent with those
of enterococcus were transferred to blood–agar slants and trans-
ported to the CDC for microbiologic confirmation as enterococcus
and identification of the species,
 
13
 
 vancomycin-susceptibility test-
ing,
 
14
 
 and molecular typing by pulsed-field gel electrophoresis.
 
15
 
Isolates of vancomycin-resistant enterococci that were obtained dur-
ing our surveys in 1998 and 1999 were compared with isolates
obtained during the initial survey in 1997 and with isolates ob-
tained in late 1996 and 1997 that were requested in 1998 from
three medical centers within 160 to 480 km (100 to 300 mi) of
Sioux City, Iowa.
 
Epidemiologic Studies
 
In October 1998, a case–control study was conducted to assess
risk factors for gastrointestinal colonization with vancomycin-resist-
ant enterococci. A patient was defined as any patient in a health
care facility of the Siouxland District Health Department who was
found to have gastrointestinal colonization with vancomycin-resist-
ant enterococci during the point-prevalence survey. Control pa-
 
*Adapted from the recommendations of the Siouxland Vancomycin-Resistant Enterococci Task Force.
 
11
 
†Patients at high risk are patients who have been hospitalized longer than 72 hours, those with clinically significant underlying medical conditions (pa-
tients undergoing dialysis, patients with cancer, and transplant recipients), those in intensive care, and those undergoing prolonged treatment with antimi-
crobial agents or with invasive devices.
‡A change in health status or treatment with antimicrobial agents may warrant the reestablishment of precautions.
§The following criteria (listed in order of importance) must be met: roommate cannot be immunosuppressed or have broken skin or renal failure; room-
mate and patient who is positive for vancomycin-resistant enterococci must be coherent and able to wash their hands and observe other infection-control
practices; patient who is positive for vancomycin-resistant enterococci cannot have diarrhea, urinary incontinence, or draining wound.
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A
 
CUTE
 
 C
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 F
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-T
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 C
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 F
 
ACILITY
 
Screening (by the culture of 
perianal swabs)
On admission Patients who are transferred from acute care facilities out-
side the community
Patients who are admitted from acute care facilities whose 
vancomycin-resistant enterococci status is unknown 
should be evaluated for risk factors† and screened if ap-
propriate; contact precautions should be implemented 
until final results are known
At discharge Not recommended for patients who are being discharged 
to long-term care facilities, if stay was less than 72 hr 
and patient did not receive antimicrobial agents
No recommendations
At other times Patients at high risk (if indicated)† Patients at high risk (if indicated)†
At time at which termination 
of precautions is considered
Follow CDC recommendations
 
12
 
‡ Follow CDC recommendations
 
12
 
‡
Isolation and infection-control
precautions
Room assignment Private or with other patients positive for vancomycin-
resistant enterococci
Private or with other patients positive for vancomycin-
resistant enterococci; can share room with a patient 
negative for vancomycin-resistant enterococci if both 
patients meet specific criteria§
Vancomycin-resistant entero-
cocci status
System of identifying the records of patients with infection 
or colonization
System of identifying the records of patients with infection 
or colonization
Barrier precautions Use of gloves for direct patient contact; use of gowns for 
substantial contact with patient and patient’s body fluids
Use of gloves for direct patient contact; use of gowns for 
substantial contact with patient and patient’s body fluids
Hand washing Health care workers, patients, and visitors Health care workers, patients, and visitors
Care of equipment Dedicated use of noncritical equipment; cleaning or dis-
infecting of equipment with approved disinfectants
Dedicated use of noncritical equipment; cleaning or disin-
fecting of equipment with approved disinfectants
Education Educational materials provided for health care workers, 
patients, and visitors
Educational materials provided for health care workers, pa-
tients, and visitors
Communication within facilities Vancomycin-resistant enterococci status of patient indi-
cated orally and written on transfer sheets
Vancomycin-resistant enterococci status of patient indicat-
ed orally and written on transfer sheets
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tients without gastrointestinal colonization with vancomycin-resist-
ant enterococci were randomly selected from facilities that had
patients with colonization. Patients and controls were compared
with regard to demographic characteristics, clinical and functional
status, prior admission to a health care facility, and prior treat-
ment with antimicrobial agents.
 
8,9,16-19
 
Site Visits and Infection-Control Assessment
 
In 1998, site visits were performed at acute care and long-term
care facilities to review the policies of each facility regarding the
control of vancomycin-resistant enterococcal infections and com-
pare them with the answers to previously distributed institutional
questionnaires. In 1999, a follow-up infection-control questionnaire
was administered. The rates of screening of patients for vancomy-
cin-resistant enterococci, isolation or grouping (“cohorting”) of
patients colonized or infected with vancomycin-resistant entero-
cocci, and infection-control policies in 1997, 1998, and 1999 were
compared.
 
Use of Antimicrobial Agents
 
On the day of the site visit to a long-term care facility, staff mem-
bers were asked to provide the number of patients during the pre-
vious week who had been prescribed antimicrobial agents. One
acute care facility in Sioux City was also asked to provide the num-
ber of patients admitted and the number prescribed vancomycin in
1997 (before the intervention) and 1998 (after the intervention).
 
Statistical Analysis
 
Data were collected on standardized forms, entered into the
computer, and analyzed with use of Epi Info (version 6.03, CDC,
Atlanta) and SAS software (version 6.12, SAS Institute, Cary, N.C.).
The prevalence rates for each year were compared with the use of
a crude chi-square test, Mantel–Haenszel adjusted chi-square test,
and a chi-square test for trend. For the case–control study, categor-
ical variables were compared with the use of the Mantel–Haenszel
chi-square test, with each facility considered as a stratum. Odds
ratios and 95 percent confidence intervals were calculated.
 
RESULTS
 
Characteristics of the Facilities and Patients
 
All 32 health care facilities located within 80 km
(50 mi) of Sioux City participated in the survey of
the prevalence of vancomycin-resistant enterococci in
1998, and 30 (4 acute care and 26 long-term care
facilities) participated in 1999. Of the 32 health care
facilities, 13 of the 28 long-term care facilities (46
percent) and 2 of the 4 acute care facilities (50 per-
cent) were located in the Sioux City metropolitan ar-
ea. Two of the four acute care facilities were referral
centers for regional community hospitals; these two
facilities had intensive care, burn, and cardiothoracic-
surgery units.
We collected swabs from 1954 of 2196 eligible pa-
tients in 1998 (89 percent) and 1820 of 2049 eligible
patients in 1999 (89 percent). The overall and facility-
specific rates of participation were similar in 1997,
1998, and 1999 (Table 2). Infection-control person-
nel in the acute care facilities reported that patients
in obstetrics and surgery wards frequently declined
to participate or were unavailable because the day of
the survey was the day of their procedure. Eleven of
the long-term care facilities in both 1998 and 1999
had participation rates of 100 percent.
 
Prevalence of Vancomycin-Resistant Enterococci
 
Twenty-nine patients were identified as being col-
onized with vancomycin-resistant enterococci in 1998
(overall prevalence, 1.5 percent) and nine in 1999
(overall prevalence, 0.5 percent). All isolates were 
 
En-
terococcus faecium,
 
 with minimal inhibitory concen-
trations of vancomycin of at least 256 µg per millili-
ter. In the 30 facilities that participated in all three
years of the survey, there were 40 patients with coloni-
zation with vancomycin-resistant enterococci in 1997
(2.2 percent), 26 in 1998 (1.4 percent), and 9 in
1999 (0.5 percent). The two facilities that chose not
to participate in 1999 had no patients who were col-
onized with vancomycin-resistant enterococci in 1997
and had three patients who were colonized in 1998.
When we compared the prevalence rates in 1997 with
those in 1998 and with those in 1999, the overall
rates and the facility-specific rates had decreased (Ta-
ble 3).
In 1997, 15 facilities (3 acute care and 12 long-
term care facilities) had at least one patient with van-
comycin-resistant enterococci. In contrast, 10 facili-
ties (3 acute care and 7 long-term care facilities) in
 
*A total of 32 facilities (4 acute care and 28 long-term care facilities) participated in the 1997 and
1998 surveys, and a total of 30 facilities (4 acute care and 26 long-term care facilities) participated
in the 1999 survey.
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 1998, 
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T
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OF
 
 F
 
ACILITY
 
1997 1998 1999
 
NO
 
.
 
ELIGIBLE
NO
 
.
 
CULTURED
 
 (%)
 
NO
 
.
 
ELIGIBLE
NO
 
.
 
CULTURED
 
 (%)
 
NO
 
.
 
ELIGIBLE
NO
 
.
CULTURED (%)
All 2266 1934 (85) 2196 1954 (89) 2049 1820 (89)
Acute care 286 152 (53) 315 165 (52) 289 170 (59)
Long-term care 1980 1782 (90) 1881 1789 (95) 1760 1650 (94)
The New England Journal of Medicine 
Downloaded from nejm.org at VIRGINIA COMMONWEALTH UNIV on January 22, 2015. For personal use only. No other uses without permission. 
 Copyright © 2001 Massachusetts Medical Society. All rights reserved. 
1430 · N Engl J Med, Vol. 344, No. 19 · May 10, 2001 · www.nejm.org
The New England Journal  of  Medicine
1998 and only 5 facilities (all long-term care facili-
ties) in 1999 had at least one patient with vancomycin-
resistant enterococci. In 1999, among the 17 patients
with vancomycin-resistant enterococci in a long-term
care facility who had been identified in the 1998 sur-
vey, 12 (71 percent) had died and 1 (6 percent) had
been discharged from the facility.
Case–Control Study of Risk Factors for Colonization
In the 1998 case–control study, we compared 29
patients with vancomycin-resistant enterococci (from
all 32 participating facilities) with 114 controls. When
we analyzed acute care facilities, patients were signif-
icantly more likely than controls to have been in the
hospital at least 3 days, to have had at least one hos-
pital admission in the 6 months before the study, to
have received a single type of antimicrobial agent for
at least 14 days, to have received an extended-spec-
trum cephalosporin, to have had diarrhea, and to have
had a urinary catheter (Table 4). Only one patient,
a control, had received intravenous vancomycin.
When we compared long-term care facilities, we
found that patients were significantly more likely than
controls to have been admitted to a hospital in the
six months before the study, to have been admitted
to hospital A (the acute care facility that had the
highest prevalence of vancomycin-resistant entero-
cocci in the 1997 survey), and to have been treated
with an antimicrobial agent in the six months before
the study (Table 5). None of the patients or controls
in long-term care facilities had received vancomycin
in the previous six months.
Of the two patients in a long-term care facility
who had no prior hospital admission within the 12
months before the 1998 study, one had been admit-
ted from a hospital before the 1997 study and had
had urinary colonization with vancomycin-resistant
enterococci before being transferred. Only one set of
two patients newly identified in 1998 were in adjoin-
ing rooms at one long-term care facility; no newly
identified patients with colonization or infection were
in the same room.
Evaluation of Infection-Control Policies
We received infection-control questionnaires from
all 32 facilities in 1998 and from 29 of 30 facilities in
1999 (97 percent). In 1998, we visited 3 of 4 acute
care facilities (75 percent) and 27 of 28 long-term
care facilities (96 percent). In 1998, 24 of 32 facilities
(75 percent) reported ever having had a patient who
was colonized with vancomycin-resistant enterococci:
3 of 4 acute care facilities (75 percent) and 21 of 28
long-term care facilities (75 percent). By 1999, 26
of 29 facilities (90 percent) reported ever having had
such a patient: all 4 acute care facilities (100 percent)
and 22 of 25 long-term care facilities (88 percent).
Screening and Identification of Colonized Patients 
with Vancomycin-Resistant Enterococci
In 1997, the screening policies of acute care facil-
ities were not assessed. In 1998 and 1999, all four
acute care facilities reported that they used aggres-
sive screening policies, which included screening pa-
tients at high risk, such as those undergoing hemo-
dialysis or in intensive care units; screening patients
on wards where clusters of colonization of infection
with vancomycin-resistant enterococci had occurred;
and screening all patients before they were discharged
to a long-term care facility. In 1997, only 9 of 28
long-term care facilities (32 percent) had a policy re-
garding screening for vancomycin-resistant entero-
cocci. In contrast, in 1998 and 1999, more than 90
percent reported having such a policy (26 of 28 [93
percent] and 23 of 25 [92 percent], respectively).
For both acute care and long-term care facilities,
the proportion of all patients who were colonized
with vancomycin-resistant enterococci who were iden-
tified by screening was significantly higher in 1998
*Only data from the 30 facilities that participated in all three years of the study were included. VRE denotes vancomycin-resistant entero-
cocci, and CI confidence interval.
†The results of the chi-square test for trend for the overall rates for 1997, 1998, and 1999 were also significant (P<0.001).
TABLE 3. PREVALENCE OF COLONIZATION WITH VANCOMYCIN-RESISTANT ENTEROCOCCI AMONG PATIENTS OR RESIDENTS 
OF 30 ACUTE CARE AND LONG-TERM CARE FACILITIES IN THE SIOUXLAND REGION IN JULY 
AND AUGUST 1997, OCTOBER 1998, AND OCTOBER 1999.*
TYPE OF FACILITY COLONIZATION WITH VRE 1998 VERSUS 1997 1999 VERSUS 1998 1999 VERSUS 1997†
1997 1998 1999
RELATIVE RISK
(95% CI) P VALUE
RELATIVE RISK
(95% CI) P VALUE
RELATIVE RISK
(95% CI) P VALUE
no. of patients (%)
All 40 (2.2) 26 (1.4) 9 (0.5) 0.6 (0.4–1.1) 0.08 0.4 (0.2–0.8) 0.005 0.2 (0.1–0.5) <0.001
Acute care 10 (6.6) 9 (5.5) 0 0.8 (0.4–2.0) 0.67 0 0.002 0 <0.001
Long-term care 30 (1.7) 17 (1.0) 9 (0.5) 0.6 (0.3–1.0) 0.05 0.6 (0.2–1.3) 0.14 0.3 (0.2–0.7) 0.001
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than in 1997 (for acute care facilities, 0 of 10 in 1997
vs. 9 of 9 in 1998, P<0.001; for long-term care fa-
cilities, 7 of 30 in 1997 vs. 10 of 20 in 1998, P=
0.05; data were available for 32 facilities in 1997 and
1998; data were unavailable for 1999).
Infection-Control Practices
Information about policies regarding the isolation
of patients who were positive for vancomycin-resist-
ant enterococci, the recommended precautions to take
in caring for such patients, and the degree to which
the policies and procedures were enforced in 1997
was mainly anecdotal. In 1998 and 1999, all 4 acute
care facilities reported following the CDC recom-
mendations,12 and most of the long-term care facili-
ties that responded to our questions indicated that
they isolated patients who were positive for vanco-
mycin-resistant enterococci or grouped them togeth-
er (21 of 23 in 1998 [91 percent]; 22 of 25 in 1999
[88 percent]). In 1999, 2 of the 22 long-term care
*Odds ratios were derived from a Mantel–Haenszel procedure, with each facility considered as a stratum (i.e., each
patient was matched to a control from the same facility). CI denotes confidence interval.
†The Kruskal–Wallis nonparametric test (not matched) was used.
TABLE 4. POTENTIAL RISK FACTORS FOR COLONIZATION WITH VANCOMYCIN-RESISTANT
ENTEROCOCCI IN ACUTE CARE FACILITIES.
POTENTIAL RISK FACTOR
PATIENTS WITH
COLONIZATION
(N=9)
CONTROLS
(N=32)
MATCHED ODDS RATIO
(95% CI)* P VALUE
Categorical variables
Exposure to health care facility — no. (%)
Length of stay »3 days
Prior hospital admission (within 6 mo)
9 (100)
9 (100)
13 (41)
16 (50)
Undefined
Undefined
0.006
0.03
Exposure to antimicrobial agents
Treatment with a single agent for »14 days
Treatment with extended-spectrum cephalosporin
Clinical factors
Diarrhea
Urinary catheter
2 (22)
6 (67)
3 (33)
4 (44)
0
3 (9)
2 (6)
2 (6)
Undefined
14.1 (3.1–63.8)
16.5 (1.7–164)
14.3 (1.3–137)
0.05
0.001
0.006
0.01
Continuous variables
Total days of treatment with antimicrobial agents†
Median
Range
12
0–37
1
0–33 — 0.003
*Odds ratios were derived from a Mantel–Haenszel procedure, with each facility considered as a
stratum (i.e., each patient was matched to a control from the same facility). CI denotes confidence
interval.
†Hospital A is the acute care facility that had the highest rate of vancomycin-resistant enterococci
in the 1997 prevalence survey.
‡Matched confidence intervals could not be calculated.
TABLE 5. POTENTIAL RISK FACTORS (CATEGORICAL VARIABLES) FOR COLONIZATION 
WITH VANCOMYCIN-RESISTANT ENTEROCOCCI IN LONG-TERM CARE FACILITIES.
POTENTIAL RISK FACTOR
PATIENTS WITH
COLONIZATION
(N=20)
CONTROLS
(N=82)
MATCHED ODDS RATIO
(95% CI)* P VALUE
no. (%)
Prior hospital admission (within 6 mo) 15 (75) 28 (34) 5.9 (1.7–20.8) 0.003
Prior admission to hospital A† 9 (45) 7 (9) 41.2‡ <0.001
Length of stay <6 mo before positive 
culture obtained
8 (40) 18 (22) 2.4 (0.9–4.7) 0.08
Treatment with antimicrobial agent 
within preceding 6 mo
18 (90) 55 (67) 4.6 (1.1–20.4) 0.04
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facilities with policies (9 percent) required patients
who were positive for vancomycin-resistant enterococ-
ci to be isolated in their rooms at all times and staff
members to adhere strictly to contact precautions.
Twenty long-term care facilities (91 percent) modified
the CDC recommendations by allowing such patients
to go outside their rooms for individual or group ac-
tivities if they were capable of washing their hands
and either were continent of stool or had their body
fluids contained; providing ways to clean equipment
used by these patients outside their rooms, such as
wheelchairs; or encouraging the use of waterless hand
sanitizers for workers and patients in lieu of strin-
gent isolation.
Use of Antimicrobial Agents
Among patients in long-term care facilities, a me-
dian of 8 percent in 1998 (range, 0 to 18 percent) and
7 percent in 1999 (range, 2 to 23 percent) had been
treated with antimicrobial agents within the week be-
fore the infection-control visit. Data on the use of
intravenous vancomycin that were provided by one
acute care facility in Sioux City showed a decrease in
vancomycin use from 1997 (483 of 11,658 admis-
sions [4.1 percent]) to 1998 (383 of 11,677 admis-
sions [3.3 percent], P<0.001).
Molecular Epidemiologic Findings
Genomic typing by pulsed-field gel electrophore-
sis was performed on 25 of 26 isolates of vancomycin-
resistant enterococci (96 percent) obtained in 1998
and all 9 obtained in 1999. Four genotypes accounted
for all 40 of the isolates obtained in 1997,10 as com-
pared with 10 genotypes for the 25 isolates obtained
in 1998 and 7 genotypes for the 9 isolates obtained
in 1999. In 1997, one clone, type A, predominated
and accounted for 85 percent of the isolates. In 1998,
type A accounted for 58 percent of the isolates, and
in 1999, type A was not identified.
From the 1996 and 1997 isolates of vancomycin-
resistant enterococci obtained from three large referral
medical centers in the midwestern United States, one
isolate from a facility in Iowa approximately 480 km
(300 mi) from Sioux City was indistinguishable from
type A. Isolates from the two other referral centers
were not related to any of our Siouxland isolates.
DISCUSSION
In July and August 1997, we evaluated the extent
of colonization with vancomycin-resistant enterococci
among patients in 32 health care facilities in the
Siouxland District Health Department. Because of
the rapid emergence of vancomycin-resistant entero-
cocci in 1997, a variety of control measures were im-
plemented. In October 1998 and October 1999, we
returned to evaluate the effect of the intervention.
Virtually all published reports support the hypoth-
eses that once vancomycin-resistant enterococci are
introduced, the rates of colonization and infection in-
crease and vancomycin-resistant enterococci become
endemic unless effective control measures are intro-
duced.2,6,9 Thus, without intervention, the preva-
lence of vancomycin-resistant enterococci in Sioux-
land health care facilities would have been expected
to increase. Instead, the overall rate of colonization
decreased from 2.2 percent in 1997 to 0.5 percent in
1999 at the 30 facilities that participated in all three
years of the study.
In 1995, the CDC published recommendations to
prevent the emergence and spread of vancomycin-
resistant enterococci that included the identification
and isolation of patients colonized with vancomycin-
resistant enterococci, hand washing by health care
workers, and cleaning of the environment.12 These
recommendations were written specifically for acute
care facilities and may need to be modified for long-
term care facilities. We found increases in the screening
of patients and compliance with recommended pre-
cautions in facilities of the Siouxland District Health
Department in 1998 and 1999 as compared with
1997. Despite variations in the application of the CDC
recommendations at long-term care facilities, most pa-
tients who were colonized with vancomycin-resistant
enterococci who were identified in our prevalence
survey had already been identified by screening pro-
grams at the various facilities. By following the CDC
recommendations, these health care facilities were able
to turn the tide and reduce in long-term care facili-
ties or eliminate in acute care facilities the transmis-
sion of vancomycin-resistant enterococci. They have
also prevented the emergence of serious infections
with vancomycin-resistant enterococci, as evidenced
by the fact that there have been no bloodstream or
invasive infections with vancomycin-resistant entero-
cocci in these facilities since the intervention. In addi-
tion, the collaboration among the facilities has fostered
communication and eased the transfer of patients col-
onized with vancomycin-resistant enterococci between
facilities, in contrast to the usual limitation of access
for such patients.
The risk factors for colonization with vancomycin-
resistant enterococci in both 1997 and 1998 were the
use of antimicrobial agents and prior exposure to acute
care facilities.10 The rate of use of vancomycin in
these facilities is low and may have decreased further
since the intervention by the task force.
There are several limitations to our study. Cul-
tures were obtained from a smaller proportion of pa-
tients in acute care facilities than in long-term care
facilities, which may have limited assessment of the
prevalence of vancomycin-resistant enterococci in
these facilities. However, participation rates were
similar in 1997, 1998, and 1999, and cultures were
obtained from most patients at high risk. In the only
acute care facility that had closed a unit because of
infections with vancomycin-resistant enterococci in
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early 1997, cultures were obtained from 89 percent
of patients.
We were able to perform all three evaluations in
only 30 of the 32 facilities. However, the two long-
term care facilities that did not participate in all three
surveys had only about 100 residents.
As with any perianal screening for vancomycin-
resistant enterococci, colonization of some patients
may not be detected by only one swab. However, the
medium we used is part of a validated method of
screening for vancomycin-resistant enterococci and
is the same medium that is used by the laboratories
of the participating facilities and that is recommend-
ed by the CDC for screening.12
In conclusion, we evaluated the efficacy of an in-
fection-control strategy in an entire region that was
implemented in order to prevent the emergence of
an antimicrobial-resistant pathogen. The success of the
intervention resulted from the collaboration among
the participating health departments, the Siouxland
District Health Department, and the personnel of the
health care facilities. In an era of emerging antimi-
crobial resistance, when many facilities are abandoning
efforts to control transmission, especially of vanco-
mycin-resistant enterococci and methicillin-resistant
Staphylococcus aureus, this comprehensive, community-
wide health care effort should be viewed as a model
for action. Our data show that comprehensive efforts
to identify and isolate patients who are colonized with
vancomycin-resistant enterococci can reduce the trans-
mission of these strains and even eradicate them.
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